Vraylar (Cariprazine) is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of bipolar disorder and schizophrenia. It primarily works by modulating dopamine and serotonin activity in the brain. Before we discuss Cariprazine Bipolar Connection, here is a glimpse into how this drug works, its indications, active ingredients, precautions,

Beyond bipolar disorder, Vraylar is also approved for treating major depressive disorder (MDD) as an adjunct therapy and schizophrenia. Its dopamine-modulating effects are under investigation for conditions such as Alzheimer’s-related agitation and other mood disorders.

Cariprazine Bipolar Connection

Pathophysiology of bipolar disorder bipolar disorder is characterized by episodes of mania (increased energy), hypomania (a less severe form of mania), and depression (persistent sadness causing behavioral changes). These mood fluctuations result from dysregulated neurotransmitter activity, particularly in dopamine (DA), serotonin (5-HT), and glutamate pathways.

Receptors in the brain are protein molecules that help transmit chemical signals from outside the brain to inside.

Cariprazine (VRAYLAR) functions as a partial agonist at D3 and D2 dopamine receptors and has the capability to bind and interact with serotonin 5-HT1A receptors. This dual action helps:

• Stabilize dopamine imbalances, preventing excessive activity (mania) and low activity (depression).
• Improve cognitive function and emotional regulation.
• Modulate serotonin to enhance mood stability.

Indications

Vraylar is FDA-approved for:

Bipolar I disorder (for manic, mixed, and depressive episodes)

Schizophrenia

Adjunct treatment for Major Depressive Disorder (MDD)

Dosage and Administration

Minimum Age Requirements

Approved for adults (18+ years).

Not recommended for pediatric patients due to insufficient safety data.

Titration and Dosage Increase

• Bipolar mania/schizophrenia: Start at 1.5 mg/day, increase to 3-6 mg/day as needed.
• Bipolar depression: Start at 1.5 mg/day, with a target dose of 1.5-3 mg/day.
• Dosage adjustments should be made cautiously due to a long half-life (1-3 weeks).

Important: According to Vraylar, “Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis.”

Precautions

Elderly patients with dementia-related psychosis have an increased risk of death when using antipsychotics.

Metabolic risks: May cause weight gain, diabetes, and high cholesterol.

Tardive dyskinesia (TD): Long-term use may lead to involuntary movements.

Pregnancy and breastfeeding: May cause fetal harm; avoid during pregnancy unless necessary.

Metabolism of Vraylar: Role of CYP3A4

Cariprazine (VRAYLAR) is primarily metabolized in the liver by the CYP3A4 enzyme. Since CYP3A4 activity varies among individuals due to genetic polymorphisms, some patients may metabolize the drug more slowly or more rapidly, leading to:

• Slower metabolizers: Higher drug accumulation, increasing the risk of side effects. Even a normal dose may cause side effects.
• Rapid metabolizers: Faster clearance, possibly reducing therapeutic efficacy.

CYP3A4 inhibitors (e.g., ketoconazole) can increase Vraylar levels, while CYP3A4 inducers (e.g., rifampin) can lower its effectiveness. An at-home PGx test (pharmacogenomics test) by RPh LABS giving you insights into your genetic makeup can show how your body may respond to 250+ medications.

Cariprazine Cessation

• Should not be stopped abruptly due to withdrawal symptoms (e.g., insomnia, mood instability, dizziness).
• Tapering under medical supervision is recommended.

Side Effects

Common Side Effects Serious Side Effects Drowsiness Neuroleptic Malignant Syndrome (NMS) Nausea Severe weight gain/metabolic syndrome Restlessness (Akathisia) Suicidal thoughts (rare) Tremors Increased risk of stroke (elderly) Weight Gain May cause uncontrolled body movements that won’t go even after your quick Vraylar Increase in High Blood Sugar Low blood pressure

Do NOT drive or operate machinery unless you know how Vraylar affects you.

Vraylar Alternatives: Comparison Table

Medication Drug Class Indications Metabolism Common Side Effects Latuda (Lurasidone) Atypical Antipsychotic Bipolar Depression, Schizophrenia CYP3A4 Nausea, Akathisia Abilify (Aripiprazole) Atypical Antipsychotic Bipolar Disorder, Schizophrenia, MDD CYP2D6, CYP3A4 Weight Gain, Restlessness Seroquel (Quetiapine) Atypical Antipsychotic Bipolar Disorder, Schizophrenia, Depression CYP3A4 Sedation, Weight Gain Risperdal (Risperidone) Atypical Antipsychotic Bipolar Disorder, Schizophrenia CYP2D6 Increased Prolactin, Weight Gain

Cariprazine Genome-Based Dosing?

Pharmacogenomics (PGx) testing can help personalize Vraylar dosage by identifying genetic variations in CYP3A4 and dopamine receptor genes.

• Patients with CYP3A4 poor metabolism may need lower doses to prevent side effects.
• Dopamine receptor (DRD3) polymorphisms may influence response rates.
• PGx testing allows clinicians to adjust treatment for optimal therapeutic effects with minimal risks.

Conclusion

Vraylar (Cariprazine) is a dopamine-serotonin modulating antipsychotic that is effective for bipolar disorder, schizophrenia, and MDD. As it is metabolized by the CYP3A4 enzyme, pharmacogenomic testing that gives insights into your genetic makeup could be beneficial for dose adjustments. Vraylar side effects, just like most antipsychotics, include weight gain that contributes to cardiovascular diseases, abnormal movement of the face and body, jerky movement, and even sudden deaths of elderly who are suffering from dementia-related psychosis. Not approved for patients living with dementia-related psychosis.

References:

https://www.vraylar.com/amdd/faqs#:~:text=Elderly%20people%20with%20dementia%2Drelated,patients%20with%20dementia%2Drelated%20psychosis.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8712443/

FAQs